Company news

Hyloris Pharmaceuticals SA news in 2026

Hyloris Pharmaceuticals SA's news releases, calls and decks from 2026, newest first.

View company

Consolidated 2026 Half-Year Report: Hyloris Delivers 56% Revenue Growth and Its Lowest Half-Year Net Loss Since IPO, Advances Its Mavericks, Core Drivers and Promising Seeds

September 28, 2026

Hyloris Pharmaceuticals: Regulated Information Hyloris’ Annual General Shareholders Meeting on June 9, 2026 ENGLISH VERSION

May 8, 2026

Hyloris Pharmaceuticals: Regulated Information Hyloris releases Annual Report 2025 ENGLISH VERSION

April 30, 2026

Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones

March 26, 2026

Hyloris Pharmaceuticals: Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension ENGLISH VERSION

February 19, 2026

Hyloris Pharmaceuticals Provides Update on FDA Review of Valacyclovir for Oral Suspension

February 19, 2026

Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdings

February 2, 2026

Hyloris Pharmaceuticals Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets

January 19, 2026

Decks in 2026